Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a.
AML
MDM2
WIP1
novel therapeutic targets
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
06 Apr 2021
06 Apr 2021
Historique:
received:
01
03
2021
revised:
23
03
2021
accepted:
27
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
In acute myeloid leukemia (AML), the restoration of p53 activity through MDM2 inhibition proved efficacy in combinatorial therapies. WIP1, encoded from
Identifiants
pubmed: 33917342
pii: biomedicines9040388
doi: 10.3390/biomedicines9040388
pmc: PMC8067413
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 19226
Organisme : ERA-Net Cofund
ID : ERA Net Grant 779282
Références
Cancer. 2019 Mar 1;125(5):712-725
pubmed: 30480765
PLoS One. 2019 Jun 26;14(6):e0217521
pubmed: 31242196
Haematologica. 2009 Jan;94(1):131-4
pubmed: 18838472
J Hematol Oncol. 2016 Jun 28;9(1):50
pubmed: 27353420
Oncogene. 2015 Nov 26;34(48):5900-11
pubmed: 25823026
Oncotarget. 2016 May 24;7(21):31563-71
pubmed: 26883196
Mol Cell. 2006 Sep 1;23(5):757-64
pubmed: 16949371
Mol Cancer Ther. 2016 Mar;15(3):379-91
pubmed: 26832796
Mol Med Rep. 2014 Jul;10(1):191-4
pubmed: 24788664
Cancer Cell. 2007 Oct;12(4):342-54
pubmed: 17936559
Blood. 2017 Aug 10;130(6):699-712
pubmed: 28607134
Cell Cycle. 2015;14(3):375-87
pubmed: 25659035
Cancers (Basel). 2018 May 31;10(6):
pubmed: 29857559
Sci Rep. 2015 Jun 30;5:11777
pubmed: 26123729
PLoS One. 2013;8(3):e60775
pubmed: 23556002
Anticancer Res. 2014 Jun;34(6):2919-25
pubmed: 24922655
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Blood. 2005 Nov 1;106(9):3150-9
pubmed: 16014563
EMBO J. 2009 Oct 21;28(20):3196-206
pubmed: 19713933
Cell Signal. 2020 May;69:109552
pubmed: 32032660
Oncol Rep. 2020 Oct;44(4):1561-1573
pubmed: 32945487
JAMA Oncol. 2016 Mar;2(3):370-2
pubmed: 26847329
Br J Cancer. 2015 Mar 17;112(6):1114-20
pubmed: 25742468
Cell Cycle. 2010 Feb 1;9(3):472-8
pubmed: 20081365
Cell Death Dis. 2016 Apr 14;7:e2195
pubmed: 27077811
Front Genet. 2019 May 03;10:411
pubmed: 31130988
J Neurooncol. 2008 Feb;86(3):245-56
pubmed: 17932621
Br J Cancer. 2018 Feb 20;118(4):495-508
pubmed: 29235570
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Cancer Res. 2009 Oct 15;69(20):7960-8
pubmed: 19808970
Br J Haematol. 2008 Sep;142(5):802-7
pubmed: 18573112
Haematologica. 2016 May;101(5):e185-8
pubmed: 26869629
Exp Ther Med. 2014 Aug;8(2):430-434
pubmed: 25009596
Cell Stem Cell. 2018 Nov 1;23(5):700-713.e6
pubmed: 30388424
Cancer Res. 2010 May 15;70(10):4112-22
pubmed: 20460517
Sci Rep. 2016 Sep 13;6:33272
pubmed: 27619510
J Biosci. 2018 Mar;43(1):25-47
pubmed: 29485113
EMBO J. 2017 Jul 14;36(14):2161-2176
pubmed: 28607002
Curr Opin Oncol. 2015 Nov;27(6):433-44
pubmed: 26418235
Breast Cancer Res Treat. 2007 Mar;101(3):269-78
pubmed: 16897432
Oncogene. 2017 Jul 13;36(28):3943-3956
pubmed: 28288132
J Cell Biol. 2013 May 13;201(4):511-21
pubmed: 23649806
Cell Cycle. 2013 Jan 15;12(2):251-62
pubmed: 23255129
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
J Clin Lab Anal. 2020 May;34(5):e23171
pubmed: 31901183
Nat Med. 2014 Dec;20(12):1472-8
pubmed: 25326804
Blood. 2018 Sep 13;132(11):1095-1105
pubmed: 29954749
Blood. 2012 Mar 1;119(9):2114-21
pubmed: 22186996
Leukemia. 2006 Oct;20(10):1899-903
pubmed: 16871279
Oncol Lett. 2017 Feb;13(2):875-880
pubmed: 28356972
Oncotarget. 2016 Mar 22;7(12):14458-75
pubmed: 26883108
Pathol Oncol Res. 2020 Jan;26(1):387-395
pubmed: 30374621
Cell Cycle. 2020 Feb;19(4):479-491
pubmed: 31959038
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Cell Death Discov. 2017 Apr 03;3:17018
pubmed: 28417018
Oncogene. 2012 Feb 9;31(6):752-63
pubmed: 21725357
Blood. 2002 Jun 15;99(12):4326-35
pubmed: 12036858
Cell Death Differ. 2014 Jun;21(6):956-66
pubmed: 24583641
Genes Dev. 2005 May 15;19(10):1162-74
pubmed: 15870257